PB101 / Panolos Biosci - LARVOL DELTA

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: Precision Biotech Taiwan Corp.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Novel Therapeutic Effect of VEGF Decoy Receptor Fusion Protein, VEGF-Grab, in Chronic Inflammatory Diseases (EULAR 2025) - "VEGF-Grab (designated as PB101 and its improved version PB102), an Fc fusion protein containing VEGFR1’s second and third Ig-like domains, demonstrates enhanced anti-angiogenic effects through novel glycosylation sites that reduce nonspecific ECM binding [4]. VEGF-Grab effectively inhibits PlGF-induced angiogenesis and reduces the pathogenic activities of RA-FLSs and Th17 cells. Its therapeutic efficacy was validated in both RA and MS animal models, with its improved version PB102 showing enhanced pharmaceutical properties and superior efficacy. By simultaneously targeting angiogenesis and inflammatory cell activity, VEGF-Grab represents a promising dual-target therapeutic approach for autoimmune diseases."

CNS Disorders • Inflammation • Inflammatory Arthritis • Multiple Sclerosis • Oncology • Rheumatoid Arthritis • Rheumatology • CSF2 • FLT1 • IFNB1 • IL17A • KDR • VEGFA

pb101: Press Briefing (EHA 2024) - No abstract available

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Panolos Bioscience

Immunomodulating • Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • FLT1

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Panolos Bioscience | Not yet recruiting ➔ Recruiting

Enrollment open • Immunomodulating • Metastases • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Panolos Bioscience

Immunomodulating • Metastases • New P1 trial • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis. (PubMed, Oncoimmunology) - "Combining PB101 and anti-PD-L1 could establish durable protective immunity against tumor recurrence and metastasis. The findings of this study offer scientific rationales for further clinical development of PB101, particularly when used in combination with immune checkpoint inhibitors, as a potential treatment for advanced cancers."

Journal • Oncology • CD8 • FLT1 • IFNG

pb101 Press Briefing (EHA 2023) - "Sponsored by Press"

Development of an Agrobacterium-delivered codon-optimized CRISPR/Cas9 system for chickpea genome editing. (PubMed, Protoplasma) - "This study transformed the single cotyledon half-embryo explants using CaMV35S promoter to drive two marker genes (β-glucuronidase gene; GUS and green fluorescent protein; GFP) through binary vectors pBI101.2 and modified pGWB2, respectively. A simple, rapid, highly reproducible, stable transformation and CRISPR/Cas9-based genome editing system for chickpea was established. This study aimed to demonstrate this system's applicability by performing a gene knockout of the chickpea PDS gene using an improved chickpea transformation protocol for the first time."

Journal

Glandular trichome specificity of menthol biosynthesis pathway gene promoters from Mentha × piperita. (PubMed, Planta) - "Several cis-elements including Myb-binding motifs together confer glandular trichome specificity as revealed from heterologous expression and analysis of menthol biosynthesis pathway gene promoters. Glandular Trichomes (GTs) are result of division of epidermal cells that produce diverse metabolites. Species of mint family are important for their essential oil containing many high-value terpenoids, biosynthesized and stored in these GTs. Hence, GTs constitute attractive targets for metabolic engineering and GT-specific promoters are important. In this investigation, the upstream regions of the Mentha × piperita menthol biosynthetic pathway genes (-)-limonene synthase, (-)-P450 limonene-3- hydroxylase, (-)-trans-isopiperitenol dehydrogenase, (-)-Isopiperitenone reductase, ( +)-Pulegone reductase, (-)-Menthone reductase/ (-)-Menthol dehydrogenase and a branched pathway gene ( +)-menthofuran synthase were isolated and characterized. These fragments, fused to..."

Journal

PB101 simultaneously targets tumor angiogenesis and immunity and enhances the efficacy of PD-L1 immune checkpoint blockade (AACR 2022) - "PB101 elicited strong anti-tumor immunity more effectively than other anti-angiogenic agents. PB101 can strengthen the immunotherapeutic efficacy of PD-L1 inhibitor by establishing a potent and durable immune memory. The combination of PB101 and PD-LI needs to be further validated in clinical trials."

Checkpoint inhibition • Clinical • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor • CD4 • CD8 • PGF • VEGFB

Samsung Biologics signs development agreement with Panolos for solid tumor treatment (PRNewswire) - "Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing. According to Panolos, PB101 is expected to suppress tumor angiogenesis more effectively by targeting VEGF-A and PlGF simultaneously, overcoming the limitations of existing treatments."

Licensing / partnership • Oncology • Solid Tumor